Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 25, 2009

TTY Biopharm to Produce to-BBB’s Brain Cancer Candidate

  • Dutch biotech company to-BBB is enlisting the help of Taiwanese drug formulation firm TTY Biopharm for the future manufacture of clinical-grade brain-targeting doxorubicin liposome candidate for the treatment of brain cancer. 

    TTY operates an EMEA-approved facility in ChangLi and already manufactures and markets Lipo-Dox®, a pegylated liposomal doxorubicin, in the Taiwanese and Asian markets. The company’s core technologies include liposomal, microemulsion, and sustained-release oral and injectable formulations.

    To-BBB’s brain-targeting doxorubicin liposome candidate is currently in preclinical development. The lead product is based on the company’s G-Technology, which involves coating the liposomes with glutathione at the tips of the polyethylene glycol. to-BBB claims the technology improves the safe delivery of free drug to the brain. The G-Technology was originally developed at the Industrial Technology Research Institute in Taiwan. 

     



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »